Dr.Β BrianΒ Druker
M.D., ABIM Board Certified
Professor of Medicine & Leukemia Specialist
corporate_fareOHSU Knight Cancer Institute, Portland, Oregon
Brian Druker
M.D., ABIM Board Certified
Dr. Brian J. Druker is a physician-scientist and internationally recognised leukemia specialist at the OHSU Knight Cancer Institute in Portland, Oregon. He is best known for his pivotal role in developing imatinib (Gleevec), a molecularly targeted therapy that transformed chronic myeloid leukaemia from a historically fatal diagnosis into a manageable condition for the majority of patients.
Dr. Druker received his M.D. from the University of California San Diego in 1981, followed by residency at Barnes Hospital, Washington University, and fellowship training in medical oncology at Dana-Farber Cancer Institute, Harvard Medical School. He has been associated with OHSU since the 1990s, serving as Director of the OHSU Cancer Institute and Knight Cancer Institute from 2007, and helping lead the $1 billion Knight Cancer Challenge that enabled major research expansion, including the Cancer Early Detection Advanced Research Center. His current clinical and research focus encompasses chronic myeloid leukaemia, BCR-ABL biology, tyrosine kinase inhibition, acute myeloid leukaemia, and integrated patient-centred cancer care. With more than 40 years of medical and research experience and an h-index of 129 from over 88,000 Scopus citations, Dr. Druker is among the most influential oncologists of his generation.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Dr. Druker at OHSU Knight Cancer Institute, subject to hospital availability and case acceptance.
Why Consider Dr. Brian Druker?
Dr. Druker helped establish the modern era of precision cancer medicine and remains one of the foremost authorities on chronic myeloid leukaemia and targeted therapy.
Areas of Specialisation
Chronic myeloid leukaemia, BCR-ABL targeted therapy, precision oncology, and leukemia clinical research
Dr. Druker's clinical and research expertise is centred on the molecular mechanisms driving leukaemia and on translating that knowledge into more effective, less toxic treatments for patients.
Chronic Myeloid Leukaemia (CML)
Comprehensive management of CML across all phases, with deep expertise in BCR-ABL biology and tyrosine kinase inhibitor therapy.
- arrow_rightImatinib (Gleevec) and second-generation TKI treatment planning
- arrow_rightMolecular response monitoring and treatment optimisation
- arrow_rightManagement of TKI resistance and treatment-free remission assessment
- arrow_rightCytogenetic and molecular assessment of Philadelphia chromosome-positive disease
- arrow_rightRisk stratification and phase assessment (chronic, accelerated, blast)
- arrow_rightLong-term follow-up and survivorship planning for CML patients
Precision Oncology & Targeted Therapy
Molecularly guided cancer treatment based on the specific genetic and protein drivers of each patient's cancer.
- arrow_rightSelection and sequencing of TKIs based on molecular profiling
- arrow_rightMonitoring of response and management of drug-related adverse effects
- arrow_rightGuidance on novel and emerging kinase inhibitors in clinical trials
- arrow_rightBiomarker-driven treatment planning across haematological malignancies
- arrow_rightIntegration of genomic data into clinical decision-making
- arrow_rightReferral and access to relevant clinical trial protocols
Leukemia Research & Clinical Trials
Active involvement in clinical research addressing unmet needs in CML, AML, and related haematological cancers.
- arrow_rightResearch and trial leadership through the Beat AML national initiative
- arrow_rightEvaluation of novel targeted agents for AML subtypes
- arrow_rightCollaborative care model connecting AML patients to active trials
- arrow_rightLeadership of the Cancer Early Detection Advanced Research Center (CEDAR) at OHSU
- arrow_rightExploration of blood-based and molecular biomarker strategies for early-stage detection
Clinical Services & Treatment Approaches
Medical oncology, targeted therapy, and leukemia care at OHSU Knight Cancer Institute
Dr. Druker's clinical practice focuses on the medical management of haematological malignancies, with particular expertise in CML and molecularly targeted therapies.
Chronic Myeloid Leukaemia Management
Medical OncologyComprehensive CML care from diagnosis through long-term molecular remission.
Targeted & Molecularly Guided Therapy
Targeted TherapyPrecision treatment planning based on the molecular and genetic profile of each patient's cancer.
Leukemia Diagnosis & Evaluation
DiagnosisComplete haematological and molecular evaluation to accurately characterise leukaemia and guide treatment planning.
Second Opinion β Leukaemia & Haematological Cancers
Second OpinionIndependent expert review for patients with CML, AML, and related haematological diagnoses.
Research & Publications
Landmark contributions to leukemia therapy, precision oncology, and cancer early detection
Dr. Druker is one of the most cited physician-scientists in oncology, with more than 547 publications, over 88,000 Scopus citations, and an h-index of 129 as listed on the OHSU Elsevier Pure profile.
A full publication list is available via the OHSU Elsevier Pure research profile. Patients with CML or AML may be eligible for active clinical trials at OHSU Knight Cancer Institute.
Education & Training
Dr. Druker trained at leading U.S. medical institutions, completing his M.D. at UCSD followed by residency and fellowship at Washington University and Harvard Medical School.
Clinical Experience
Dr. Druker has been associated with OHSU for more than three decades, building the Knight Cancer Institute into a globally recognised cancer research and treatment centre.
Languages & International
Dr. Druker consults in the following language.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Dr. Druker at OHSU.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Brian Druker
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Brian Druker's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Brian Druker's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Brian Druker before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Brian Druker's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Brian Druker's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Brian Druker's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Brian Druker
Dr. Druker is best known for his pioneering role in the development and clinical advancement of imatinib (Gleevec), a targeted therapy for chronic myeloid leukaemia (CML). His work helped establish that a cancer driven by a specific molecular defect could be selectively targeted by a drug, transforming CML from a historically fatal diagnosis into a manageable condition for most patients and helping launch the modern era of precision cancer medicine.
Dr. Druker's verified clinical and research focus is chronic myeloid leukaemia (CML), including BCR-ABL-positive and Philadelphia chromosome-positive leukaemias. He is also involved in acute myeloid leukaemia (AML) research, including the Beat AML master trial, and cancer early detection research through the OHSU CEDAR centre.
Dr. Brian Druker is based at the OHSU Knight Cancer Institute at Oregon Health & Science University in Portland, Oregon, United States.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare the case for submission, and coordinate the next steps with OHSU Knight Cancer Institute, subject to availability and case acceptance.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, cytogenetics, molecular test results (BCR-ABL PCR), imaging, and treatment history. The final consultation format and availability depend on OHSU's scheduling and case-acceptance process.
CancerFax can coordinate report review and consultation support for international patients seeking an opinion from Dr. Druker at OHSU Knight Cancer Institute, subject to hospital availability and case acceptance. Please contact CancerFax to discuss your specific situation.
Connect with Brian Druker Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.